Skip to main content
NVDA+0.63%AAPL-0.96%GOOGL-1.64%MSFT-1.16%AMZN-1.73%TSM-0.89%SPCX-2.26%META+0.33%AVGO-1.30%TSLA+0.41%SKHY-0.26%BRK-B+0.25%LLY+0.62%MU+0.46%JPM-1.58%WMT-0.43%AMD+2.05%V+0.02%XOM+2.52%JNJ-0.56%ASMLa-1.24%0700.HK+1.90%MA-0.12%INTC+1.16%ABBV+1.09%1398.HK-2.09%CSCO+0.60%CVX+1.96%BAC-0.68%ORCL-0.97%COST-1.09%KO-0.93%DELL+3.61%CAT-0.26%HSBA.L-2.32%0005.HK-3.21%PG+0.52%UNH-1.59%LRCX-2.12%AP2d-2.41%AMAT-1.08%1816.HK-0.46%3988.HK-2.13%NFLX-2.91%GE-2.94%MS-2.69%0857.HK+0.60%HD-1.36%PM-0.23%0939.HK-2.83%NZDUSD-0.99%USDJPY+0.98%CHFJPY+0.75%USDTHB+0.72%NZDCHF-0.68%NZDCAD-0.64%GBPNZD+0.63%CADJPY+0.62%AUDUSD-0.60%GBPJPY+0.59%EURUSD-0.50%EURNZD+0.49%EURJPY+0.45%GBPTRY+0.41%AUDNZD+0.39%AUDJPY+0.39%PLNJPY+0.38%GBPUSD-0.36%USDCAD+0.36%NOKJPY+0.34%NZDMXN-0.33%GBPHKD+0.32%USDCHF+0.31%GBPMXN-0.28%AUDCHF-0.28%SGDJPY+0.27%USDTRY+0.25%USDSEK+0.23%AUDCAD-0.23%GBPAUD+0.22%GBPZAR-0.21%USDSGD+0.20%NZDSGD-0.19%EURCAD-0.17%EURCHF-0.17%USDILS+0.16%EURSEK+0.16%USDNOK+0.13%EURSGD+0.13%EURCZK+0.11%EURAUD+0.11%EURGBP-0.11%EURZAR-0.10%AUDDKK-0.09%USDPLN+0.09%CHFNOK-0.08%GBPCHF-0.07%USDCNH+0.07%USDDKK+0.07%USDMXN+0.06%EURHKD-0.06%EURNOK+0.06%CADCHF-0.05%USDCOP-0.04%AUDSGD+0.04%AUDNOK-0.03%USDZAR-0.03%EURCNH-0.03%CHFSEK+0.03%USDHKD+0.03%EURPLN+0.02%GBPSGD+0.01%GBPCAD-0.01%CHFSGD-0.01%NZDJPY-0.01%EURDKK0.00%USOIL+2.34%COCOA-2.21%W1+1.59%COFFEE-1.46%UKOIL+1.25%SUGAR-1.07%XNGUSD+0.92%S1+0.86%C1+0.73%HG1+0.49%COTTON-0.46%XAUUSD-0.26%BTCUSD-2.28%ETHUSD-3.49%USDTUSD-0.03%XRPUSD-2.14%SOLUSD-3.08%TRXUSDT-0.53%ZECUSDT-3.09%DOGEUSD-2.19%XMRUSDT+0.47%LINKUSD-2.02%XLMUSD+0.95%BCHUSDT-1.25%UNIUSD-2.86%LTCUSD-2.32%HBARUSDT+0.42%TONUSD+26.79%SUIUSD-2.51%TAOUSDT-2.71%AAVEUSD-2.03%DOTUSDT-1.81%ICPUSDT-6.99%ONDOUSDT-3.09%WLDUSDT-1.29%ARBUSDT+8.56%ATOMUSDT-0.78%JUPUSDT-4.30%INJUSDT-9.40%STXUSDT-3.11%FETUSDT-4.17%PYTHUSDT-4.06%TIAUSDT-5.86%SEIUSDT-2.47%IMXUSDT-1.00%OPUSDT-1.70%GRTUSDT-3.85%POLUSDT+0.51%WIFUSDT-4.27%IOTAUSDT-5.57%AXSUSDT-2.78%FARTCOINUSDT-1.39%EOSUSDT-4.33%DYDXUSDT-5.84%ORDIUSDT-1.67%GALAUSDT-1.47%NOTUSDT-2.37%RONINUSDT-12.83%NVDA+0.63%AAPL-0.96%GOOGL-1.64%MSFT-1.16%AMZN-1.73%TSM-0.89%SPCX-2.26%META+0.33%AVGO-1.30%TSLA+0.41%SKHY-0.26%BRK-B+0.25%LLY+0.62%MU+0.46%JPM-1.58%WMT-0.43%AMD+2.05%V+0.02%XOM+2.52%JNJ-0.56%ASMLa-1.24%0700.HK+1.90%MA-0.12%INTC+1.16%ABBV+1.09%1398.HK-2.09%CSCO+0.60%CVX+1.96%BAC-0.68%ORCL-0.97%COST-1.09%KO-0.93%DELL+3.61%CAT-0.26%HSBA.L-2.32%0005.HK-3.21%PG+0.52%UNH-1.59%LRCX-2.12%AP2d-2.41%AMAT-1.08%1816.HK-0.46%3988.HK-2.13%NFLX-2.91%GE-2.94%MS-2.69%0857.HK+0.60%HD-1.36%PM-0.23%0939.HK-2.83%NZDUSD-0.99%USDJPY+0.98%CHFJPY+0.75%USDTHB+0.72%NZDCHF-0.68%NZDCAD-0.64%GBPNZD+0.63%CADJPY+0.62%AUDUSD-0.60%GBPJPY+0.59%EURUSD-0.50%EURNZD+0.49%EURJPY+0.45%GBPTRY+0.41%AUDNZD+0.39%AUDJPY+0.39%PLNJPY+0.38%GBPUSD-0.36%USDCAD+0.36%NOKJPY+0.34%NZDMXN-0.33%GBPHKD+0.32%USDCHF+0.31%GBPMXN-0.28%AUDCHF-0.28%SGDJPY+0.27%USDTRY+0.25%USDSEK+0.23%AUDCAD-0.23%GBPAUD+0.22%GBPZAR-0.21%USDSGD+0.20%NZDSGD-0.19%EURCAD-0.17%EURCHF-0.17%USDILS+0.16%EURSEK+0.16%USDNOK+0.13%EURSGD+0.13%EURCZK+0.11%EURAUD+0.11%EURGBP-0.11%EURZAR-0.10%AUDDKK-0.09%USDPLN+0.09%CHFNOK-0.08%GBPCHF-0.07%USDCNH+0.07%USDDKK+0.07%USDMXN+0.06%EURHKD-0.06%EURNOK+0.06%CADCHF-0.05%USDCOP-0.04%AUDSGD+0.04%AUDNOK-0.03%USDZAR-0.03%EURCNH-0.03%CHFSEK+0.03%USDHKD+0.03%EURPLN+0.02%GBPSGD+0.01%GBPCAD-0.01%CHFSGD-0.01%NZDJPY-0.01%EURDKK0.00%USOIL+2.34%COCOA-2.21%W1+1.59%COFFEE-1.46%UKOIL+1.25%SUGAR-1.07%XNGUSD+0.92%S1+0.86%C1+0.73%HG1+0.49%COTTON-0.46%XAUUSD-0.26%BTCUSD-2.28%ETHUSD-3.49%USDTUSD-0.03%XRPUSD-2.14%SOLUSD-3.08%TRXUSDT-0.53%ZECUSDT-3.09%DOGEUSD-2.19%XMRUSDT+0.47%LINKUSD-2.02%XLMUSD+0.95%BCHUSDT-1.25%UNIUSD-2.86%LTCUSD-2.32%HBARUSDT+0.42%TONUSD+26.79%SUIUSD-2.51%TAOUSDT-2.71%AAVEUSD-2.03%DOTUSDT-1.81%ICPUSDT-6.99%ONDOUSDT-3.09%WLDUSDT-1.29%ARBUSDT+8.56%ATOMUSDT-0.78%JUPUSDT-4.30%INJUSDT-9.40%STXUSDT-3.11%FETUSDT-4.17%PYTHUSDT-4.06%TIAUSDT-5.86%SEIUSDT-2.47%IMXUSDT-1.00%OPUSDT-1.70%GRTUSDT-3.85%POLUSDT+0.51%WIFUSDT-4.27%IOTAUSDT-5.57%AXSUSDT-2.78%FARTCOINUSDT-1.39%EOSUSDT-4.33%DYDXUSDT-5.84%ORDIUSDT-1.67%GALAUSDT-1.47%NOTUSDT-2.37%RONINUSDT-12.83%
AP

ACADIA Pharmaceuticals Inc. (ACAD)

NASDAQ • Healthcare

$27.52
-$0.3 (-1.1%)
Market open

Last close at September 14, 2026 at 20:00 UTC

Open$28
Previous Close$27.52
Day Range$27.38 - $28.1
Avg. Volume (3M)1.4M
Market Cap$4.6B
P/E Ratio12.2
52 Week Range
$19.69$30.96
Next EarningsIn 50 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$307.9M100%
Gross Profitminus cost of goods$279.6M91%
Operating Incomeminus R&D and overhead$37.8M12%
Net Incomeminus taxes and the rest$31.5M10%

In plain terms: out of every $100 in revenue, ACADIA Pharmaceuticals Inc. keeps $10 as net profit.

Fundamentals & Financials

Revenue (TTM)
$1.1B
Net Income (TTM)
$380.4M
EPS (TTM)
$2.25
ROA (TTM)
21.83%
Current Ratio
3.39

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+1067.9%Q1 2026$1.6
-50.0%Q2 2026$0.02
+164.1%Q3 2026$0.18
Next

Nov 4

in 50 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +164.1%

ACADIA Pharmaceuticals beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported August 4, with EPS of $0.18 topping the $0.07 estimate (+164%) as revenue of $308.0 million topped the $296.6 million estimate (+3.8%). Revenue rose ~16% to about $308.0 million (up from about $264.6 million a year ago), while profitability stayed high with gross margin near 91% and operating margin around 12%, alongside operating income of roughly $37.8 million. Net income increased ~18% to about $31.5 million, compared with roughly $26.7 million a year ago, and EPS rose 12.5% from $0.16. The company generated operating cash flow of about $134.8 million during the quarter. For the next period, consensus calls for EPS of $0.20 on revenue of $332.3 million.

View full earnings history

About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. develops and commercializes small-molecule therapies for central nervous system disorders and operates in biotechnology within the healthcare sector. The NASDAQ-listed company trades as ACAD, and its only marketed product, NUPLAZID, helped generate $1.1 billion of revenue in FY2025.

Name
ACADIA Pharmaceuticals Inc.
CEO
Catherine E. Owen Adams
Website
www.acadia.com
Industry
Healthcare
Year Founded
1993
Employees
797

Today's Snapshot

AI-generated

The session opened with ACAD slightly lower at 27.51, while its sector was flat.

Trading Volume

Below 10d avg (1.3M)

174.1K

vs S&P 500 Today

Underperforming Market

-1.53%

Updated: September 15, 2026 at 14:41 UTC

Technical Indicators

3 Buy1 Neutral4 Sell
ACAD’s near-term technicals are skewed lower despite some longer-term support, with short- and medium-term moving averages trading above the price and momentum measures negative. CCI and MACD readings point to downside pressure, while RSI sits in neutral-leaning territory; ADX indicates a modest trend rather than a strong directional impulse. Volume on balance shows accumulation, and stochastic and Williams %R readings suggest the stock is oversold and vulnerable to a bounce, but the pivot remains overhead as resistance. Technical takeaway: Sell — near-term indicators favor downside even as longer-term averages offer partial support.
All signals
  • EMA (5 indicators)$25.04 - $28.16
    Sell
  • RSI (14)39.47
    Neutral
  • Stochastic %K (14, 3, 3)10.86
    Buy
  • MACD Level (12, 26)-0.11
    Sell

Peers & Related Assets

PRAXPraxis Precision Medicines, Inc.
$330.55-1.2%
CRNXCrinetics Pharmaceuticals, Inc.
$84.950.0%
IMVTImmunovant, Inc.
$37.66+0.8%
MIRMMirum Pharmaceuticals, Inc.
$96.75-1.5%
LGNDLigand Pharmaceuticals Incorporated
$280.65-1.3%
VKTXViking Therapeutics, Inc.
$31.53-1.4%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.